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Abstract
The hazard ratio is routinely used as a summary measure to assess the treat-
ment effect in clinical trials with time-to-event endpoints. It is frequently
assumed as constant over time although this assumption often does not hold.
When the hazard ratio deviates considerably from being constant, the aver-
age of its plausible values is not a valid measure of the treatment effect, can be
clinically misleading and common sample size formulas are not appropriate.
In this paper, we study the hazard ratio along time of a two-component
composite endpoint under the assumption that the hazard ratio for each
component is constant.
This work considers two measures for quantifying the non-proportionality
of the hazard ratio: the difference D between the maximum and minimum
values of hazard ratio over time and the relative measure R representing the
ratio between the sample sizes for the minimum detectable and the average
effects. We illustrate D and R by means of the ZODIAC trial where the
primary endpoint was progression-free survival.
We have run a simulation study deriving scenarios for different values of
the hazard ratios, different event rates and different degrees of association
between the components. We illustrate situations that yield non-constant
hazard ratios for the composite endpoints and consider the likely impact on
sample size.
Results show that the distance between the two component hazard ratios
plays an important role, especially when they are close to 1. Furthermore,
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even when the treatment effects for each component are similar, if the two-
component hazards are markedly different, hazard ratio of the composite is
often non-constant.
Keywords: Non-Proportional Hazard, Treatment Effect, Composite
endpoint, Randomized Controlled Trial, Progression-Free Survival, Copula
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1. Introduction
The selection of the primary endpoint (PE) is a key decision which should
be made at the first stage of a study. The combination of two or more out-
comes in randomized controlled trials (RCTs) is often considered for the
evaluation of the efficacy of new treatments and interventions as it could
represent a more comprehensive clinical picture [1]. Composite endpoints
(CEs), defined as the union of several outcomes, are extensively used when
designing a clinical trial. In time-to-event studies, CE refers to the elapsed
time from randomization until the earliest observation among its compo-
nents. For example, it is common in oncological trials to use progression
free survival (PFS): this outcome is defined as the time elapsed between
randomization and objective tumor progression (OTP) or death from any
cause, whichever occurs first [2]. Also, in cardiovascular trials, major ad-
verse cardiac event (MACE) is generally defined as a composite endpoint
that includes the time to cardiovascular death, myocardial infarction, stroke
and target vessel revascularization [3].
When evaluating the treatment effect on a time-to-event endpoint in an
RCT, the hazard ratio (HR) is routinely used as a summary measure of
treatment effect. When the PE is a CE, the hazard ratio of the CE, HR(t),
might vary over time. In those cases where HR(t) is approximately constant,
its average over time may appropriately capture the relative treatment effect
between arms. However, otherwise, it should not be understood as an average
[4] and the common formulae to calculate sample sizes are not valid [5].
Nowadays more studies are encountered with non-constant hazard ra-
tios and several reasons may explain why [6]: i) many new therapies being
evaluated have different modes of action, for example, the effect of the inter-
vention might persist during the treatment period but diminishes afterwards,
ii) phase III trials are much larger and therefore there are more chances to
detect non-proportional hazards (NPH) [7], and iii) with the intention of
testing smaller treatment effects, composite endpoints are used more often
[8] leading often to NPH. Indeed, it is proved that even under the assumption
that for each component the hazards are proportional, the resulting hazards
for the CE are not necessarily proportional [9].
This paper discusses under which circumstances the hazard ratio of a CE
may potentially result in greater departure from constancy and its impact
on sample size. We base our evaluation on several simulated scenarios that
represent realistic clinical trial situations. We illustrate the problem by means
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of a case study. Specifically, in this work, we provide: 1) two measures (D
and R) as indicators of the non-proportionality of the hazards of the CE;
2) a list of factors (prioritizing according to their importance) that have
an impact on the non-proportionality and consequently, on the sample size
calculation; and 3) a threshold for the R indicator above which the premise
of the proportionality of the hazards is not reasonable. The final goal is to
provide informed guidelines and warnings about the use of a constant HR
when the deviation from constancy is remarkably high.
2. Material and Methods
2.1. Notation and settings
Consider an RCT comparing a new therapy (group g = 1) versus the
standard therapy or control (g = 0) with respect to a primary composite
endpoint E∗ where E∗ is the union of two different endpoints, E1 and E2, for
instance, overall survival (OS) and OTP. We assume that the components
forming the CE are relevant for the objectives of the trial and their combi-
nation is clinically meaningful. Furthermore, the new therapy is supposed to
be effective in the same direction for both endpoints, for instance, reducing
the number of events.
In such an RCTs, individuals are followed until the event of interest (E1
or E2) or until the end of the study, whichever occurs first. If we denote by
T
(g)
1 and T
(g)
2 the times to E1 and E2, respectively, for individuals from group
g, the time until the occurrence of E∗, in group g, consisting of the earlier
occurrence of E1 or E2, is denoted by T (g)∗ . Denote by HR1 and HR2, the
hazard ratios for E1 and E2, respectively, and assume that both are constant,
as commonly done and denote by HR∗(t), the hazard ratio for E∗. We assume
that HRk < 1 (k = 1, 2) implying that the new therapy reduces the risk of
both events E1 and E2.
In order to study and characterize HR∗(t), the hazard ratio for E∗, we
need the following functions and parameters for g = 0, 1: i) a joint distri-
bution between T
(g)
1 and T
(g)
2 , constructed using Frank’s copula [10]; ii) the
marginal probability distributions for T
(g)
1 and T
(g)
2 chosen from a Weibull
family because of its flexibility to represent different life-time data scenar-
ios, allowing increasing, constant (exponential model) and decreasing hazard
functions; iii) the probabilities p
(0)
1 and p
(0)
2 of observing events E1 and E2
during follow-up up to τ in the control group (g = 0); iv) the constant haz-
ard ratios HR1 and HR2 for E1 and E2, respectively, and v) the measure of
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association between T
(g)
1 and T
(g)
2 , given by means of Spearman’s rank cor-
relation ρ(g) -we assume ρ(0) = ρ(1) = ρ . The reader is referred to [11] for
technical details concerning the computation of HR∗(t).
In our setup we are considering that one of the events is fatal, say E1,
hence E2 would not be observed if it would happen after E1. We are therefore
in a competing risks situation where the parameters governing the marginal
distribution for T
(g)
2 have to be constrained to the observed values of T
(g)
2
prior to T
(g)
1 , that is, the probability of observing endpoint T
(g)
2 is calculated
as p
(g)
2 = Prob{T (g)2 < τ, T (g)2 < T (g)1 } where τ is the common censoring time
corresponding to the end of the study.
2.2. Non-Proportional Hazards Indicators
If the effect of the treatment markedly changes during the period of follow-
up, then the hazard ratio may vary over time. In order to capture the
treatment effect in such cases, the options that the researchers may consider
are: 1) the maximum value MHR∗ of the hazard ratio HR∗(t), representing
the minimum detectable effect; 2) the minimum value mHR∗ of the hazard
ratio HR∗(t), representing the maximum detectable effect; 3) the average
value aHR∗ of the hazard ratio HR∗(t) [12]; or 4) other constant summaries
[5]. While MHR∗ and mHR∗ are never representative of the treatment effect
when the hazard ratio varies over time, aHR∗ could be a valid summary of
the treatment effect if the HR∗(t) is reasonably constant.
Aiming to quantify the non proportionality of the HR∗(t) we propose two
measures: i) the absolute difference between the maximum (MHR∗) and the
minimum (mHR∗) values of the HR∗(t) denoted by D:
D = MHR∗ −mHR∗ (1)
and ii) for a given significance level α and power, the ratio between the
sample size of the minimum detectable effect, nMHR∗ and the sample size of
the average effect naHR∗ , denoted by R:
R =
nMHR∗
naHR∗
(2)
These two measures complement each other: while D provides a first
intuitive quantification of how far the treatment effect is from being constant
over time and of the impact of the non-proportionality on the effect size, the
impact of the non-proportionality on the sample size is captured by R with
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larger values of R implying larger sample sizes. For the same distance D
between MHR∗ and aHR∗, the measure R takes larger values when aHR∗ <
MHR∗ is closer to 1.
In the results section, their interpretation will be expanded.
2.3. Sample size and R
Following [13, 14] and assuming the same censoring rate for each group,
at a one-tailed significance level α the number of events (eh) and sample size
(nh) required to detect a treatment effect h < 1 with power 1− β are given
by:
eh = 4(zα + zβ)
2/(log h)2 (3)
nh = 2eh/(p
(0) + p(1)) (4)
where β is the probability of type II error; zα and zβ are the standard normal
quantiles corresponding to α and β, respectively; and p(g) is the probability
of observing the event in group g during the study. It can be shown that the
relative measure R is
R =
(
log(aHR∗)
log(MHR∗)
)2
=
nMHR∗
naHR∗
(5)
naHR∗ provides the sample size based on the average value of HR∗(t) as treat-
ment effect while nMHR∗ is an upper bound of the sample size obtained for
the minimum detectable effect. If HR∗(t) is constant, naHR∗ should be close
to nMHR∗ and hence R close to 1. Otherwise, R values away from 1 indicate
that conventional sample size formulas for constant HR(t) can not be used.
2.4. Simulation Study Settings
The behaviour of the hazard ratio HR∗(t) for the composite of two end-
points is studied for a variety of scenarios based on different parameter values
as shown in Table 1. We have chosen parameter values for simulation that
represent realistic scenarios when designing an RCT [11].
The probabilities p
(0)
1 and p
(0)
2 of observing each component event in the
control group have been taken between 0.1 and 0.5; the cause-specific hazard
ratios HR1 and HR2 of each component represent large to small treatment
effects (from 0.6 to 0.9); the correlations between the time to each endpoint
have been selected from low to moderate (from ρ = 0.1 to ρ = 0.5); and
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Parameters
p
(0)
1 , p
(0)
2 0.1 0.3 0.5
HR1, HR2 0.6 0.7 0.8 0.9
ρ 0.1 0.3 0.5
Distribution (Decr. hazards) (Exponential) (Incr. hazards)
β1, β2 0.5 1 2
Number
of scenarios 3 888
Table 1: Parameter setting to generate the simulation scenarios. p
(0)
k are the probabilities
of observing each component Ek in the control group; HRk are the constant cause-specific
hazard ratios for each event Ek; ρ stands for the Spearman’s rank correlation; βk are the
shape parameters of the Weibull distribution for Ek. The total number of scenarios are
derived from all possible combinations (32 × 42 × 3× 32).
the times until the component endpoints (Ek, k = 1, 2) have been modeled
according to Weibull distributions with constant (βk = 1), decreasing (βk =
0.5) or increasing hazards (βk = 2). For simplicity, the follow-up time has
been set constant and equal to 1 in all scenarios without involving any loss
of generalisability in the results.
3. Results
3.1. ZODIAC trial
ZODIAC trial [15] compared the efficacy of the Vandetanib plus docetaxel
versus docetaxel as second-line treatment in patients with advanced non-
small-cell lung cancer. Statistically significant differences were found in the
composite primary endpoint, PFS, taken as the union of OS and OTP.
The reported cause-specific HRs for each component were 0.91 (OS) and
0.77 (OTP) and the probabilities of observing each component event in the
control group were 0.59 and 0.74, respectively. Furthermore, we know that
the estimated HR of the composite event, PFS, was 0.79. From these data,
we explore a couple of situations with different resulting interpretations. Fig-
ure 1 shows the shape of the hazard ratio for PFS, HR∗(t), during the study
in two different scenarios. Assuming a moderate association (ρ = 0.5) be-
tween OS and OTP, if the marginal times to death and OTP follow exponen-
tial distributions (constant hazards), then HR∗(t) would be almost constant
fluctuating in a narrow range from 0.78 to 0.81 over time (orange curve in the
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left plot) and with aHR∗, average of HR∗(t), during follow-up, equal to 0.79
which is consistent with the reported hazard ratio. aHR∗ = 0.79 represents
a 21% relative reduction in the risk of death or OTP in the treatment arm
(Vandetanib plus docetaxel) as compared with the control arm (docetaxel).
In this situation, the average aHR∗ would be a good approximation of the
treatment effect at any instant of time. However, if as it often does, the haz-
ards of OTP are increasing, regardless of the treatment arm, then the HR∗(t)
for PFS could vary markedly (along time) taking extreme values from 0.76
up to 0.91 (orange curve in the right plot). Obviously, in this case, although
the value of aHR∗ is the same as in the previous scenario (0.79), it is not
representative at all of the treatment effect over time.
0.6
0.7
0.8
0.9
1.0
Start of the study End of the study
H
a
z
a
rd
 R
a
ti
o
OS OTP PFS
0.6
0.7
0.8
0.9
1.0
Start of the study End of the study
H
a
z
a
rd
 R
a
tio
OS OTP PFS
Figure 1: HRs over time in ZODIAC trial under two different scenarios. Dark and light
blue lines are the cause-specific hazard ratios for Overall Survival (OS) (HROS = 0.91)
and Objective Tumor Progression (OTP) (HROTP = 0.77), respectively. Orange line
represents the hazard ratio for the composite endpoint (HR∗(t)) over time. In both plots,
the probabilities of OS and OTP in the control group are p
(0)
OS = 0.59 and p
(0)
OTP = 0.74,
respectively, and a moderate correlation (ρ = 0.5) is assumed between the events. The
difference between the two plots is due to the different distributions of the times TOS
and TOTP : while in the left plot, an exponential distribution is assumed for both events,
the right plot assumes a Weibull distribution with increasing hazards for OTP and an
exponential distribution for OS.
The assumed distributions for the individual components significantly
affect the sample size calculations in both situations of Figure 1. If both dis-
tributions are exponential, implying constant hazards (Figure 1, left), despite
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the small difference (D = 0.03) between the MHR∗ (0.81) and mHR∗ (0.78),
the implication on the sample size is significant: the indicator R is equal to
1.25, implying an increase of 25% in the number of patients. However, it is
even worse if the hazards increase over time in the OTP endpoint (Figure 1,
right): now, the difference in the HRs (D = 0.15) implies serious concerns in
the sample size since R increases up to 6.25 leading to an increase of 525%
if minimum detectable effect is considered for the sample size calculations.
In the ZODIAC trial, 1,176 events were considered enough to reach a
power of 0.9 to detect a HR equal to or less than 0.8 with a 0.05 significance
level. The study obtained a p value = 0.0001 for PFS with a larger effect size
than that specified in the sample size calculations, which facilitated reaching
statistical significance. Panel A in Figure 2 of [15] shows the Kaplan-Meier
curves for PFS; despite their similar behavior during the first two months for
both arms, the subsequent gradual separation does not point out a violation
of the proportional hazards assumption.
All these results have been obtained using the CompARE platform (http:
//cinna.upc.edu:3838/compare/CompARETimeToEvent/), which is a web-
site specifically created for the design of clinical trials with composite end-
points. It allows, among others, to perform sample size calculations and to
draw the HR∗(t) depending on some input parameters, such as the cause-
specific hazard ratios, the probabilities of observing each event or the corre-
lation between outcomes.
3.2. Understanding D and R measures
Figure 2 shows the HR∗(t) function for three different settings (orange
lines). These scenarios only differ in the behaviour of the hazard of the
time to each component (see legend of Figure 2). We observe that identical
departures indicated by D can have different implications. For instance,
the dashed and dotted lines have similar behaviour over time and the same
extreme values (mHR∗ = 0.84 and MHR∗ = 0.90) and thus, the same
absolute difference D = 0.06; however, the measure R takes distinct values
in both scenarios (R = 1.81 and R = 1.98), indicating that the required
number of patients using MHR∗ is respectively 81% and 98% larger than if
HR∗(t) is summarized by the average aHR∗.
The right axis of Figure 2 represents the number of events to achieve a
power=0.8 using the formula (3) at a one-sided significance level α = 0.05
using the corresponding HR indicated on the left axis. It can be seen that
the number of events substantially increase in the range from a hazard ratio
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Figure 2: Behaviour of the HR∗(t) (orange) for PFS in three different scenarios. HROS
and HROTP are the cause-specific hazard ratios of each component: E1 = death (dark
blue) and E2 = OTP (light blue). The probabilities of observing the events during the
study in the control group are p
(0)
OS = 0.15 and p
(0)
OTP = 0.5, respectively, with a correlation
coefficient ρ = 0.3. The three scenarios are characterized by the hazards behaviour over
time in the distributions of TOS and TOTP : a) increasing (OS)/constant (OTP) – dotted
line–; b) constant (OS)/decreasing (OTP) – dashed line–; and c) decreasing (OS)/constant
(OTP) – semidotted line–. Left vertical axis represents the hazard ratio and right vertical
axis represents the needed sample size at a one-sided significance level α = 0.05 with power
1− β = 0.8 depending on the corresponding HR at left. Indicators of non-proportionality
(D and R) are placed next to the line representing each situation.
h = 0.8 to h = 0.9. For this reason, minor fluctuations in this area have
great repercussions on the sample size. For instance, in both, the dashed
and dotted lines (PFS1 and PFS2), the required number of events based on
the MHR∗ is around 2,200 while based on the average hazard ratio aHR∗,
only about 1,200 and 1,100 events are required, respectively.
Following the example in Figure 2, we depict the HR for PFS with the
semi-dotted line (PFS3) in this case, with a decreasing hazard function for
OS, and a constant hazard for OTP. The behaviour of HR∗(t) is markedly
different from earlier to later times of follow-up, producing a much larger ab-
solute difference D = 0.27. If we now compare the dashed and semi-dotted
lines, we observe that the same R = 1.81 leads to a noticeable difference be-
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tween ranges (D = 0.06 and 0.27, respectively). As it will be seen later, the
choice of the distribution of each component in the sample size determination
is paramount: small differences of the anticipated value for HR could dra-
matically change the required number of events (specially for hazard ratios
close to 1, as we will discuss later) and vice versa.
In the simulation study presented next, we will study under which sit-
uations there is a greater departure of constancy for the HR∗(t) and the
consequences in the calculation of the sample size.
3.3. Simulation Study
We will assess under which scenarios the premise of proportional hazards
will be more compromised in terms of sample size implications, and for this
reason the R indicator will be used during this section. Under the parameter
setting in Table 1, Table 2 reports on the influence of the input parameters
(treatment effects, hazard behaviour and correlation) on the measure R.
R
Minimum Median Maximum
Treatment effect
HR1 = HR2 1 1.05 1.35
|HR1 −HR2| = 0.1 1 1.20 3.49
|HR1 −HR2| = 0.2 1 1.49 8.18
|HR1 −HR2| = 0.3 1 2.06 15.65
Laws of each component
Both decreasing hazards (β1 = β2 = 0.5) 1 1.04 1.23
Both constant (β1 = β2 = 1) 1 1.04 1.28
Both increasing hazards (β1 = β2 = 2) 1 1.06 1.44
Different behaviour in hazards (β1 6= β2) 1.01 1.39 15.65
Correlation
Weak (ρ = 0.1) 1 1.07 14.97
Mild (ρ = 0.3) 1.01 1.13 15.19
Moderate (ρ = 0.5) 1.01 1.18 15.65
Global 1 1.15 15.65
Table 2: Range and median values of the R indicator depending on several factors: i)
absolute difference between the HRs of the components; ii) the laws of the times to each
event; and iii) the correlation between these times.
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We observe that when the treatment effects for each component are equal,
i.e. HR1 = HR2, the median value of R is 1.05, meaning a 5% of rela-
tive difference between the sample sizes required by MHR∗ and aHR∗, but
the median increases up to 2.06 when the treatment effects markedly differ
(|HR1−HR2| = 0.3). Therefore, greater concerns regarding the sample size
arise when the treatment effect in each component is noticeably different.
Furthermore, when the behaviour of the hazards is different in each end-
point (β1 6= β2), smaller effects, that is HRs close to 1, imply higher values
of the R indicator (not shown in Table 2). For instance, for an absolute
difference of the HRs equal to 0.1, the median of R is 1.23 if the HRs of
each endpoint are 0.6 and 0.7, while it is 1.60 if these HRs are 0.8 and 0.9.
When the probability distributions governing the time to each endpoint
have the same hazard, i.e., β1 = β2, the median of R under different settings
is no more than 1.06. That is, if the event times have the same shape pa-
rameter, the HR∗(t) is relatively constant. It is not the case if two endpoints
with different hazard functions are combined: the median departure from
constancy is 1.39 and can be as large as 15.65. Our results do not point
out a strong relationship between the R values and the degree of association
between component endpoints.
Figure 3 shows the complete distribution of the simulated R values under
various scenarios. Again, it can be observed that the relative measure R
depends strongly on the behavior of the hazard function for each component.
If the evolution over time of the two endpoint hazards occurs in different
directions (i.e., one with increasing hazard and the other with decreasing
one), then in almost all situations, the implications of considering a constant
HR(t) on the sample size can be much larger. Only if the treatment effects
are similar in both outcomes, this fact would be mitigated.
In the remaining scenarios, when the probability distributions governing
the time to each endpoint have the same hazard function, i.e., β1 = β2,
high R values can be only obtained if treatment effects are very different
(|HR1−HR2| ≥ 0.3) and the correlation between components are moderate
or high (ρ ≥ 0.5). In all scenarios, high correlations and different treatment
effects imply larger values of R.
3.4. Criterion to assess non-proportionality
In order to establish a criterion to decide when the average aHR∗ of
HR∗(t) is not a meaningful summary for the treatment effect on the com-
posite endpoint, we have taken into account the following: we consider that
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the HR of the CE would be remarkably non-constant if the required sample
size using MHR∗ is 25% larger than that using aHR∗. Based on this crite-
rion, we recommend a threshold of 1.25 (horizontal dashed line in each panel
of Figure 3) for R. It is worth mentioning that when the treatment effects
and/or the distributions in each component are very different, it is very likely
to exceed this threshold.
Both increasing  (ß1 =  ß2 =  2) Different behaviour (ß1 ≠  ß2)
Both decreasing  (ß1 =  ß2 =  0.5) Both constant  (ß1 =  ß2 =  1)
0 0.1 0.2 0.3 0 0.1 0.2 0.3
1.0
1.5
1.0
1.5
2.0
5.0
10.0
1.0
1.5
1.0
1.5
| HR1 − HR2 |
R
Correlation Weak (ρ = 0.1) Mild (ρ = 0.3) Moderate (ρ = 0.5) 
Figure 3: Quantification of the impact of various factors on the sample size. R indicator
as function of the hazard of each endpoint (panels), the absolute difference of the HRs
(horizontal axis) and the correlation between endpoints (color). Vertical axes represent
the R value in log-scale - note that the scale of the last panel is different from the others.
The dashed horizontal lines at R = 1.25 in each panel represent the value from which
the non-proportionality of the hazards is critical and should be taken into account in the
sample size calculations.
4. Conclusions
In randomized controlled trials it is common to use a hazard ratio as a
summary to assess the treatment effect on the time to event outcomes and
to base the sample size calculation on the constant hazard ratio defined in
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the alternative hypothesis. Since composite endpoints are frequently used
as primary endpoints in many fields, we are concerned about whether it is
reasonable to assume a constant hazard ratio for the composite endpoint and
use the standard formulae for sample size.
We have described situations where the hazard ratio for a composite end-
point is far from being constant, taking into account the behaviour of the
hazard function and the probability of observing the event of each compo-
nent for the control group as well as the association between the component
endpoints. We have seen that component endpoints arising from different
probabilistic distributions (e.g., one exponential and the other Weibull with
increasing hazards) or very different treatment effect lead almost always to
non-constant hazard ratios. In these scenarios, the average hazard ratio does
not provide a meaningful measure of the treatment effect and alternatives
such as the difference in percentiles at the end of the study or the restricted
mean survival time, defined as the expected event-free time during the follow-
up [16], should be used instead.
Next, we discuss some specific issues of our work. First, we have con-
sidered scenarios with one terminal event, such as death. This is a critical
consideration because of concerns related with competing risks. Despite the
estimation of the marginal distributions of the competing outcomes is gener-
ally infeasible [17], we can define the marginal distribution for each compo-
nent of the composite endpoint under the latent failure time model, that is,
assuming potential marginal distributions for T
(g)
1 and T
(g)
2 and obtain the
joint distribution of the two endpoints by means of a copula, even though
we are aware that this is not the unique alternative. Nevertheless, we are
not encountering any problem because T
(g)
∗ (g = 0, 1) includes the death
component, it is observable based on real data and the parameters governing
the marginal distribution for T
(g)
2 are constrained to the observed values of
T
(g)
2 prior to T
(g)
1 . Second, the choice of Spearman’s correlation as a measure
of association has been made for interpretative reasons. Other popular as-
sociation measures, such as Kendall’s τ , could be used instead. Since there
is a one-to-one correspondence between Kendall’s τ and Spearman’s ρ, the
choice of one versus the other does not have any repercussion when using
copulas to generate the joint distribution. Third, in all scenarios, we have
defined a follow-up time equal to 1 just for convenience, but the findings
can be extrapolated for any follow-up time provided that the parameters of
the distributions are scaled accordingly. Fourth, we have set a limit value of
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R = 1.25 keeping in mind that the calculation of the sample size based on a
constant HR(t) with values above this threshold can be problematic. Obvi-
ously, this threshold should be decided by each researcher paying attention
to the conditions described in this work that are more unfavorable to have
a constant hazard ratio. Fifth and last, in the case of the ZODIAC Trial,
the censoring comes from, on the one hand, the end of the study and, on
the other hand, the losses of follow-up. When performing the calculations of
Figure 1, only the end of study censoring have been considered.
Our work attempts to highlight the inappropriateness of the proportional
hazards assumption for composite endpoints in several situations, especially
when sample size is based on this erroneous premise. In those cases where
this proportionality is not fulfilled, other alternative measures should be used
and the design and statistical analysis of the clinical trial should change
accordingly. This paper is not addressing aspects of the statistical analysis
when the proportional hazards assumption does not hold.
We advocate for a thorough study of the possible patterns of the hazard
ratio for the composite endpoints before deciding on the primary endpoint for
efficacy and prior to any sample size estimation. The researcher must consider
1) if the behavior of the hazards are different among the components; 2) if the
treatment effects are different in each component; and 3) if the occurrences
of the events are somehow correlated. The more affirmative answers to these
three questions, the more likely a non-constant treatment effect over time
for the CE. For a quantitative study of the influence of these factors, one
may use the CompARE platform (http://cinna.upc.edu:3838/compare/
CompARETimeToEvent/). All these considerations should be included and
discussed in the protocol of the study allowing trialists to evaluate whether
the hazard ratio is an appropriate measure or whether other measures should
be considered for the evaluation of the treatment effect.
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